BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.

about

Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes.Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates.

P2860

Q38912064-FECDB9FF-702E-4BA9-BCF4-92F3B7D6AE27 Q45868489-8B5BB422-4EB9-4319-93F9-13690D2BFB14

P2860

BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.

Item

http://www.wikidata.org/entity/Q45865134

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

BAX326 (recombinant coagulatio ...... d prophylaxis of hemophilia B.

@en

type

Item

label

BAX326 (recombinant coagulatio ...... d prophylaxis of hemophilia B.

@en

prefLabel

BAX326 (recombinant coagulatio ...... d prophylaxis of hemophilia B.

@en

P1476

BAX326 (recombinant coagulatio ...... d prophylaxis of hemophilia B.

@en

P2093

Andrea E Hafeman

http://www.w3.org/2001/XMLSchema#string

Brigitt E Abbuehl

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database.

Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project.

Molecular cloning of the gene for human anti-haemophilic factor IX.

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.

The overall effectiveness of prophylaxis in severe haemophilia.

The epidemiology of inhibitors in haemophilia A: a systematic review.

Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.

Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products.

Back to the future: a recent history of haemophilia treatment.

Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders.

P304

333-342

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17474086.2014.903153

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

J Windyga

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24832133

http://www.w3.org/2001/XMLSchema#string

P921

hemophilia

hemophilia B

Coagulation factor IX

BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.

about

P2860

P2860

BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921